Literature DB >> 22472351

Brentuximab associated progressive multifocal leukoencephalopathy.

Pankaj Jalan1, Aman Mahajan, Vijay Pandav, Simon Bekker, Janak Koirala.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22472351     DOI： 10.1016/j.clineuro.2012.03.019

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN： 0303-8467            Impact factor:   1.876


× No keyword cloud information.
  7 in total

1.  Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project.

Authors:  Kenneth R Carson; Scott D Newsome; Ellen J Kim; Nina D Wagner-Johnston; Gloria von Geldern; Craig H Moskowitz; Alison J Moskowitz; Alain H Rook; Pankaj Jalan; Alison W Loren; Daniel Landsburg; Thomas Coyne; Donald Tsai; Dennis W Raisch; LeAnn B Norris; P Brandon Bookstaver; Oliver Sartor; Charles L Bennett
Journal:  Cancer       Date:  2014-04-25       Impact factor: 6.860

Review 2.  Current strategies for salvage treatment for relapsed classical Hodgkin lymphoma.

Authors:  Liana Nikolaenko; Robert Chen; Alex F Herrera
Journal:  Ther Adv Hematol       Date:  2017-08-29

Review 3.  Combining Biology and Chemistry for a New Take on Chemotherapy: Antibody-Drug Conjugates in Hematologic Malignancies.

Authors:  Helen Ma; Ahmed Sawas
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

4.  SEVERE INSULIN RESISTANCE WITH DIABETIC KETOACIDOSIS AFTER BRENTUXIMAB TREATMENT.

Authors:  Janet M Chiang; Andrew R Lai; Mark Anderson; Robert J Rushakoff
Journal:  AACE Clin Case Rep       Date:  2020-01-22

Review 5.  Central Nervous System Complications in Children Receiving Chemotherapy or Hematopoietic Stem Cell Transplantation.

Authors:  Duccio Maria Cordelli; Riccardo Masetti; Daniele Zama; Francesco Toni; Ilaria Castelli; Emilia Ricci; Emilio Franzoni; Andrea Pession
Journal:  Front Pediatr       Date:  2017-05-15       Impact factor: 3.418

Review 6.  Immunotoxin - a new treatment option in patients with relapsed and refractory Hodgkin lymphoma.

Authors:  Barbara Jezersek Novakovic
Journal:  Radiol Oncol       Date:  2015-11-27       Impact factor: 2.991

Review 7.  Comparison of Anticancer Drug Toxicities: Paradigm Shift in Adverse Effect Profile.

Authors:  Debasish Basak; Scott Arrighi; Yasenya Darwiche; Subrata Deb
Journal:  Life (Basel)       Date:  2021-12-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.